Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Sometimes we all struggle to try and understand what we are looking at. Here’s a sentence from a paper we have just been reading: “After transduction of myristolated-AKT (a serine/threonine protein kinase) and ERG (an ets family transcription factor), lesions resembling [PIN] … developed.”
Filed under: Uncategorized | Tagged: origin, stem cell, theory | Leave a Comment »
An article in this week’s New England Journal of Medicine has argued that an earlier report, postulating the monoclonal origin of lethal metastatic prostate cancer, increases the justification for focal therapy for early stage prostate cancer.
Filed under: Management, Treatment | Tagged: focal therapy, origin | 3 Comments »
On Tuesday this week we reported on a study suggesting that some prostate cancers might be caused by the XMRV virus. Now comes a study suggesting that specific types of stems cells may be implicated in the development of some prostate cancers.
Filed under: Prevention | Tagged: cause, origin, stem cells | Leave a Comment »
Today’s news reports focus on four items: Development of aggressive prostate cancer from a single cell and tumor Prostate size and risk for positive surgical margins Quality of urinary function after different types of surgery Gefitinib as a single agent in treatment of CRPC
Filed under: Drugs in development, Management, Treatment | Tagged: CRPC, development, gefitinib, origin, positive surgical margins, prostate size, surgery, urinary function | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site